Yes, the chart below was particularly interesting. It seems that most of the decline was during the initial dose escalation phase of the study.
If you look just at the last 4 months of both cohorts, there appears to be very little decline.
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst, page-957
-
- There are more pages in this discussion • 468 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
16.8¢ |
Change
-0.003(1.47%) |
Mkt cap ! $80.25M | |||
| Open | High | Low | Value | Volume |
| 17.0¢ | 17.0¢ | 16.5¢ | $57.91K | 343.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 217363 | 16.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.0¢ | 43978 | 1 |
View Market Depth
| Last trade - 15.32pm 18/09/2024 (20 minute delay) ? |
| PAA (ASX) Chart |